X
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis
https://pharmaphorum.com/news/nice-okays-ucbs-cimzia-nixes-almirall-ilumetri-in-psoriasis/
UCB
FDA approves UCB’s Cimzia in plaque psoriasis
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
FDA approves Pfizer’s Besponsa in aggressive blood cancer
Besponsa becomes first of its kind indicated for rare type of acute lymphoblastic leukaemia.
UCB recruits Belgian wearables firm for epilepsy study
Byteflies’ Sensor Dot will help monitor brain, heart and respiration activity.
1 2
